PUBLIC COMPANY
save$ALTAltimmune, Inc.
$ALT2.9300-2.33%Gaithersburg, MD, USupdated 8h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
- phase2IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
- phase2HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
- phase2RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
- phase1NasoShield Study of Safety and Immunogenicity
- phase1Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
- phase1NasoShield in Healthy Adults to Study Safety and Immunogenicity
- phase1ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (4)
- Feb 26, 26grantRoberts M Scot · Chief Scientific Officer222,670 sh
- Feb 26, 26grantRoberts M Scot · Chief Scientific Officer95,430 sh
- Feb 26, 26grantWEAVER GREGORY L · Chief Financial Officer259,000 sh
- Feb 26, 26grantWEAVER GREGORY L · Chief Financial Officer111,000 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that